🔗 Share this article

Chancellor Rachel Reeves has announced she is preparing "specific steps to tackle cost of living pressures" in the forthcoming financial statement.

Speaking to media outlets, she emphasized that lowering inflation is a collective task of both the administration and the central bank.

The UK's price growth is forecast to be the most elevated among the Group of Seven developed nations this year and the following year.

Possible Utility Bill Interventions

Sources suggest the government could intervene to bring down utility costs, such as by reducing the present 5% level of value-added tax applied on energy supplies.

Another possibility is to reduce some of the government charges currently added to household expenses.

Fiscal Limitations and Expert Predictions

The administration will receive the latest assessment from the independent fiscal watchdog, the OBR, on the start of the week, which will show how much space there is for such actions.

The expectation from most economists is that the Chancellor will have to declare tax increases or expenditure reductions in order to meet her voluntary debt limits.

Previously on the same day, estimates indicated there was a £22 billion deficit for the chancellor to address, which is at the lower end of forecasts.

"There's a shared task between the central bank and the government to continue tackling some of the drivers of inflation," Reeves told the BBC in the US capital, at the annual meetings of the International Monetary Fund and World Bank.

Tax Pledges and Global Concerns

While much of the focus has been on likely tax increases, the chancellor said the most recent figures from the fiscal watchdog had not altered her commitment to election pledges not to raise rates on earnings tax, sales tax or National Insurance.

She blamed an "uncertain world" with rising international and trade concerns for the Budget tax moves, likely to be directed on those "with the broadest shoulders."

International Economic Disputes

Referring to worries about the UK's commercial links with China she said: "Our national security invariably are paramount."

Last week's statement by China to tighten export controls on critical minerals and other materials that are essential for advanced tech production led US President Donald Trump to threaten an extra 100% tariff on goods from the Asian country, increasing the possibility of an full-scale commercial conflict between the two economic giants.

The US Treasury Secretary labeled China's action "commercial pressure" and "a global supply chain power grab."

Questioned on considering the US offer to join its battle with China, Reeves said she was "deeply worried" by Chinese actions and called on the Beijing authorities "to avoid restrictions and limit trade."

She said the decision was "harmful for the international commerce and causes additional headwinds."

"It is my opinion there are areas where we need to address Chinese policies, but there are also valuable opportunities to sell into China's economy, including banking sector and other areas of the economy. We've got to get that equilibrium correct."

The chancellor also affirmed she was collaborating with international partners "regarding our own essential resources strategy, so that we are reduced dependence."

Health Service Drug Pricing and Investment

The Chancellor also acknowledged that the cost the National Health Service pays for drugs could rise as a consequence of ongoing negotiations with the Trump administration and its pharmaceutical firms, in exchange for lower tariffs and funding.

Some of the world's largest pharmaceutical manufacturers have said in recent statements that they are either halting or abandoning operations in the UK, with several blaming the low prices they are receiving.

Recently, the Science Minister said the price the health service pays for medicines would need to increase to halt businesses and pharmaceutical investment leaving the United Kingdom.

The Chancellor informed media: "We have seen because of the cost structure, that clinical trials, innovative medicines have not been offered in the United Kingdom in the extent that they are in other continental states."

"Our aim is to make sure that patients receiving care from the National Health Service are can receive the finest life-saving drugs in the globe. And so we are reviewing this situation, and... aiming to attract more investment into Britain."